Kenvue Inc. (NYSE:KVUE) Shares Sold by Gulf International Bank UK Ltd

Gulf International Bank UK Ltd trimmed its position in shares of Kenvue Inc. (NYSE:KVUE) by 1.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 145,630 shares of the company’s stock after selling 1,506 shares during the period. Gulf International Bank UK Ltd’s holdings in Kenvue were worth $3,109,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. Lake Street Advisors Group LLC raised its stake in shares of Kenvue by 17.4% during the 4th quarter. Lake Street Advisors Group LLC now owns 15,919 shares of the company’s stock worth $340,000 after buying an additional 2,361 shares during the period. Longbow Finance SA raised its position in shares of Kenvue by 5.0% during the 4th quarter. Longbow Finance SA now owns 280,568 shares of the company’s stock worth $5,990,000 after purchasing an additional 13,287 shares during the last quarter. Los Angeles Capital Management LLC lifted its stake in Kenvue by 1,415.5% in the 4th quarter. Los Angeles Capital Management LLC now owns 139,684 shares of the company’s stock valued at $2,982,000 after buying an additional 130,467 shares in the last quarter. Amalgamated Bank boosted its holdings in Kenvue by 0.5% in the 4th quarter. Amalgamated Bank now owns 378,249 shares of the company’s stock worth $8,076,000 after buying an additional 1,932 shares during the last quarter. Finally, IFP Advisors Inc boosted its holdings in Kenvue by 168.4% in the 4th quarter. IFP Advisors Inc now owns 12,197 shares of the company’s stock worth $263,000 after buying an additional 7,652 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Price Performance

Shares of NYSE KVUE opened at $23.15 on Friday. The stock’s 50-day moving average is $21.42 and its two-hundred day moving average is $22.24. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a market cap of $44.24 billion, a price-to-earnings ratio of 43.67, a price-to-earnings-growth ratio of 2.62 and a beta of 1.45. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were issued a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.54%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s payout ratio is currently 154.72%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on KVUE shares. Barclays decreased their target price on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Friday, January 17th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Piper Sandler lifted their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research note on Monday. Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Finally, Canaccord Genuity Group lowered their price target on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.